Furthermore, we showed that the BDP-9066 is most effective against Claudin-low subtype breast cancer, suggesting the potential of MRCK as a new drug target for TNBC where Claudins can be used as biomarkers. The gene discussed is CDC42BPA; the disease is breast carcinoma.